Results 51 to 60 of about 2,249,117 (300)

Anti-VEGF-A antibody does not recognize VEGF-A : Incubation with VEGF-A antibody

, 2011
This antibody recognizes the VEGF-A monomer (22.5 kDa) and dimer (45 kDa) in control and glaucomatous retinas (first two lanes). VEGF-A antibody does not recognize 25 ng, 100 ng, or 250 ng of VEGF-A recombinant protein in the same membrane (last three ...
Wei Huang (36889), Diane Darland (53480), Arjun Ray (53479), Cynthia L. Grosskreutz (53482), Ceren Ergorul (53478), Zhonghui K. Luo (53481)   +5 more
core   +1 more source

Clinical significance of VEGF-A, -C and -D expression in esophageal malignancies [PDF]

, 2005
Vascular endothelial growth factors ( VEGF)- A, - C and - D are members of the proangiogenic VEGF family of glycoproteins. VEGF-A is known to be the most important angiogenic factor under physiological and pathological conditions, while VEGF-C and VEGF-D
Jauch, Karl-Walter, Kleespies, A., Bruns, Christiane J.   +2 more
core   +1 more source

Brain homeostasis : VEGF receptor 1 and 2 ; two unequal brothers in mind [PDF]

, 2013
Vascular endothelial growth factors (VEGFs), initially thought to act specifically on the vascular system, exert trophic effects on neural cells during development and adulthood.
Karl H. Plate, Plate, Karl, Wittko-Schneider, Ina M., Schneider, Fabian T., Fabian T. Schneider, Ina M. Wittko-Schneider   +5 more
core   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Combined therapy versus anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy: a Meta-analysis [PDF]

International Journal of Ophthalmology, 2017
AIM: To evaluate the efficacy and safety of anti-vascular endothelial growth factor (VEGF) combined with photodynamic therapy (PDT) versus anti-VEGF monotherapy for polypoidal choroidal vasculopathy (PCV).
Long-Hui Han1, Li-Fei Yuan1, Xu Liang2, Xin Jia1, Ming-Lian Zhang1   +4 more
doaj   +1 more source

Anti-VEGF Therapy in Myopic CNV

Current Drug Targets, 2021
In this narrative-review, we report the most recent data from the literature of anti-vascular endothelial growth factor treatment for myopic choroidal neovascularization (mCNV). Myopic CNV is the most frequent sight-threatening complication of pathologic myopia.
Lisa Toto, Luca Di Antonio, Olivia Costantino, Rodolfo Mastropasqua   +3 more
openaire   +2 more sources

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Gene expression analysis in human breast cancer associated blood vessels [PDF]

, 2012
Angiogenesis is essential for solid tumour growth, whilst the molecular profiles of tumour blood vessels have been reported to be different between cancer types.
John M J Herbert, Jones, DT, Richard Mitter, John M. J. Herbert (132335), Jones D. T., Bicknell, R, Francesca Buffa, Adrian L. Harris (132344), Li Ji-Liang, Li, J-L, Herbert, JMJ, Mitter Richard, Roy Bicknell (54952), Harris A. L., Buffa F., Buffa, Francesca, Mitter, R, Adrian L Harris, Kairbaan Hodivala-Dilke, J Louise Jones, Tanguy Lechertier, Lechertier Tanguy, Tanguy Lechertier (132331), Herbert, JM, Roy Bicknell, Kairbaan Hodivala-Dilke (132348), Herbert John M. J., Lechertier, T, Harris Adrian L., Lechertier T., Francesca Buffa (132341), Hodivala-Dilke Kairbaan, Mitter R., Hodivala-Dilke, K, Jones J. Louise, Ji-Liang Li (132339), Jones, JL, Harris, AL, Buffa, F, Richard Mitter (132333), Bicknell Roy, Li, JL, Dylan T. Jones (132329), Dylan T Jones, Jones Dylan T., Bicknell R., Ji-Liang Li, Herbert J. M. J., Li J. -L., J. Louise Jones (132337), Buffa Francesca, Jones J. L., Hodivala-Dilke K., et al,   +53 more
core   +1 more source

Initial response and 12-month outcomes after commencing dexamethasone or vascular endothelial growth factor inhibitors for retinal vein occlusion in the FRB registry

Scientific Reports
To compare baseline characteristics, initial response and 12-month efficacy and safety outcomes in eyes with branch and central retinal vein occlusion (BRVO and CRVO) treated with dexamethasone implants (DEX) or anti-vascular endothelial growth factor ...
Gonzaga Garay-Aramburu, Adrian Hunt, Carolina Arruabarrena, Hemal Mehta, Alessandro Invernizzi, Pierre-Henry Gabrielle, Tremeur Guillaumie, Benjamin Wolff, Mark C. Gillies, Javier Zarranz-Ventura   +9 more
doaj   +1 more source

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source